There is no FDA-approved branded lipotropic injection. No manufacturer can offer methionine, inositol, choline, and B12 in a single ready-to-administer ampoule, because that fixed-blend product was never developed, never submitted, and never approved. The only way to receive this combination as an injection is through a 503A compounding pharmacy, prepared on a patient-specific prescription written by a licensed prescriber for a named patient. A retail purchase off a shelf is not an option that exists.
Because the brief is built from individual components, the prescription itself is the personalization. The B12 form is chosen (cyanocobalamin versus methylcobalamin) based on whether a methylation rationale or a documented deficiency is being addressed. L-carnitine is included or excluded based on the prescriber's clinical reasoning. Ratios are adjusted, B-complex co-factors (B1, B2, B6) are added or omitted, preservative-free single-use vials are specified for patients with benzyl alcohol sensitivity, and the route (intramuscular versus subcutaneous) and frequency are set against the patient's injection-site tolerability and chart. Early human data on the combination is limited to clinic case series, so the prescription is also a documented clinical rationale rather than a marketing claim.
This is what pharmacy looked like before mass manufacturing arrived. A doctor wrote the prescription. A pharmacist prepared it for that patient. Compounded lipotropic injection is that older arrangement, kept honest by modern oversight and a refusal to fill prescriptions written as direct-to-consumer fat-burner marketing.
In brief
Lipotropic Injection (MIC, MICC) Explained
A lipotropic injection is a compounded shot made from nutrients that participate in how the liver and body process fats. The most common blend, called MIC, combines methionine (an amino acid), inositol (a sugar-like molecule), and choline (an essential nutrient) 1. Many clinics add vitamin B12. There is no FDA-approved branded lipotropic product, every dose is mixed at a compounding pharmacy from individual ingredients.
The honest evidence picture: each ingredient has well-established biology individually (methionine supports methylation and glutathione production; choline is an essential nutrient with established roles in liver fat metabolism; inositol has been studied in PCOS; B12 is essential and corrects fatigue when there is a documented deficiency) 619. But the MIC combination itself has not been tested in pivotal randomized weight-loss trials 13. RonanRx treats lipotropic injection as a possible adjunct to comprehensive metabolic care under physician supervision, not as a substitute for FDA-approved weight-loss treatments like semaglutide, tirzepatide, or bariatric surgery 27.
At a glance
Quick Facts About Lipotropic Injection (MIC, MICC)
Intramuscular or subcutaneous injection, typically administered 1, 2 times weekly in a clinic-supervised or home-use setting
FDA-approval status
No FDA-approved branded lipotropic injection product exists. Each component has its own regulatory status (e.g., cyanocobalamin injection is FDA-approved for B12 deficiency; methionine, inositol, and choline are not approved as injectable drugs for weight management).
Compounded under
503A, patient-specific prescription only. RonanRx does not dispense lipotropic injection as a routine weight-loss product.
Evidence posture
Emerging / individual-component-only. There are no pivotal randomized controlled trials of the MIC or MIC+B12 combination as a fat-loss intervention. Evidence supporting use rests on the established biology of the individual nutrients (methylation, phospholipid synthesis, glutathione precursor, B12-dependent reactions) and on small clinical-practice case series, not on combination-product RCTs.
Important regulatory caution
FDA has issued warning letters to compounding pharmacies and clinics for unsubstantiated weight-loss marketing claims about lipotropic injections, particularly when marketed direct-to-consumer outside a documented patient-specific prescription relationship. Lipotropic injection is not a substitute for FDA-approved weight-management therapy.
Prescription review
Patient-Specific Prescription Only
Lipotropic Injection (MIC, MICC) on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.
Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
Named-patient label. The bottle carries your name. The batch records carry your prescription.
Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
What is Lipotropic Injection (MIC, MICC)?
A lipotropic injection is a sterile compounded combination of B-vitamins and lipotropic-factor nutrients dispensed under 503A on a patient-specific prescription. The historical term 'lipotropic' refers to nutrients that, in classical nutrition research, were shown to promote the export and metabolism of fat in the liver, methionine, choline, and inositol were the originally described lipotropic factors. Modern compounded preparations preserve that nomenclature without implying FDA endorsement or a registered weight-loss indication.
The two most common formulations are: (1) MIC, methionine, inositol, and choline, with or without B12; and (2) MIC+ or 'lipo-Mino', MIC plus L-carnitine and additional B-vitamins (B1, B2, B5, B6) at compounder-specific concentrations 6. Each compounded preparation is mixed from individual sterile ingredients and is not bioequivalent to any other compounder's preparation. There is no reference FDA-approved branded lipotropic injection product against which a compounded preparation can be benchmarked.
Lipotropic injection is most commonly administered intramuscularly (deltoid or gluteus) or subcutaneously, weekly or twice weekly, in a clinic-supervised or home-use setting. Dose is by injection volume (typically 1 mL) at compounder-specific concentrations rather than by a standardized milligram-per-component schedule, because no consensus dose specification exists in the published literature 11729.
How it works
How Lipotropic Injection (MIC, MICC) Works
Class
Nutrient combination injection
First studied
Decades of compounded use
Common forms
Subcutaneous or intramuscular injection
Compounding category
503A, patient-specific prescription
The components of a lipotropic injection address overlapping biology rather than a single drug target. Methionine is the principal nutritional source of methyl groups, donated through S-adenosylmethionine (SAMe) to DNA, phospholipid, and protein methylation reactions; it is also a precursor to cysteine and to glutathione, the dominant intracellular antioxidant 124. Choline is required to synthesize phosphatidylcholine, which is the principal phospholipid component of VLDL particles needed to export triglyceride from hepatocytes, choline deficiency in humans causes hepatic steatosis and elevated transaminases that reverse on repletion 679.
Inositol (myo-inositol) participates in phosphoinositide signaling downstream of insulin and gonadotropin receptors 1315. Its clinical evidence base is concentrated in polycystic ovary syndrome, where meta-analyses report improvements in ovulatory function, insulin sensitivity, and metabolic markers 14. Vitamin B12 (cyanocobalamin or methylcobalamin) is a cofactor for methionine synthase (which regenerates methionine from homocysteine and folate one-carbon units) and methylmalonyl-CoA mutase; deficiency causes megaloblastic anemia, peripheral neuropathy, cognitive impairment, and fatigue 192021. L-carnitine, when present in MIC+ blends, transports long-chain fatty acids into the mitochondrial matrix for β-oxidation 2425.
The conceptual framing of a lipotropic injection is therefore that it supplies, in parenteral form, the substrate and cofactor inputs to several converging metabolic pathways: hepatic methylation and VLDL export (methionine + choline); insulin/gonadotropin signaling (inositol); homocysteine remethylation (B12 + folate, where folate is co-administered or already supplied dietarily); and mitochondrial fatty-acid oxidation (carnitine). What is not established is whether parenteral co-administration of these substrates and cofactors produces measurable fat-loss or metabolic benefit beyond what dietary repletion of any specific deficiency would achieve 17.
Research history
Lipotropic Injection (MIC, MICC) Research History
The lipotropic concept dates to the 1930s. Best, Hershey, and Huntsman (1932) described that choline added to a high-fat diet prevented hepatic lipid accumulation in dogs, coining the operational definition of a 'lipotropic factor' as a nutrient that mobilizes hepatic fat. Methionine and inositol were subsequently identified as having related effects in rodent models of hepatic steatosis 14. This animal literature established the methionine-choline-deficient (MCD) dietary paradigm that remains in use as a preclinical NASH model.
Human research on the individual components developed over the second half of the twentieth century. The Institute of Medicine established Adequate Intakes for choline in 1998 6. The controlled human choline-depletion studies of Buchman, Zeisel, and colleagues, beginning in the 1990s and 2000s, established that adult humans require choline as an essential nutrient and that choline-free parenteral nutrition causes reversible hepatic steatosis 879. The methionine-homocysteine-folate-B12 cycle was characterized in detail through the 1990s, 2010s 12. The therapeutic role of vitamin B12 repletion in B12 deficiency anemia and neurologic disease was established by mid-twentieth-century work and remains foundational 192021. The clinical literature on inositol in polycystic ovary syndrome developed through the 2000s and 2010s, with Unfer and colleagues publishing the principal meta-analyses 131514. Population-level dietary-choline assessment showed that the majority of US adults do not meet the AI 11.
What did not develop, in parallel, was a published randomized clinical trial literature for the lipotropic-injection combination product itself. There is no FDA-registered phase I, II, or III trial of MIC or MIC+B12 injection as a weight-management or metabolic intervention 16. The clinical-practice tradition of compounded lipotropic injection is documented in chart reviews, case series, and aesthetic-medicine practice descriptions, not in pivotal trials. FDA enforcement actions and warning letters in the 2010s and 2020s have specifically addressed unsubstantiated weight-loss marketing claims by compounding pharmacies and clinics for lipotropic preparations 27. The McCall et al. (2026) FAERS pharmacovigilance analysis of compounded injectable preparations 26 documents the broader pattern of adverse events specific to compounded sterile injectables that cannot be predicted from individual-component evidence.
Timeline
Lipotropic Injection (MIC, MICC) Timeline
1932Best, Hershey, and Huntsman describe the lipotropic effect of choline on hepatic fat in dogs, the origin of the term 'lipotropic factor' (referenced in 6)
1994Buchman et al 8. (Clin Pharmacol Ther) characterize intravenous choline pharmacokinetics in human subjects
1998Institute of Medicine establishes Adequate Intake (AI) values for choline as an essential nutrient for adults (referenced in 6)
2001Buchman et al 7. (JPEN), placebo-controlled trial showing choline deficiency causes reversible hepatic abnormalities in adults receiving parenteral nutrition; proof of a human choline requirement
2006Brosnan & Brosnan (J Nutr) publish an overview of the sulfur-containing amino acids, anchoring methionine's role in methylation and glutathione synthesis 1
2009Zeisel & da Costa (Nutrition Reviews), Choline: an essential nutrient for public health 6
2012Corbin & Zeisel (Curr Opin Gastroenterol), Choline metabolism provides novel insights into NAFLD and its progression 9
2012Carlomagno, Unfer et al 15. (Gynecol Endocrinol), systematic review of myo-inositol RCTs in PCOS
2012Nordio & Proietti (Eur Rev Med Pharmacol Sci), myo-inositol + D-chiro-inositol combination vs myo-inositol alone in PCOS 16
2012Anstee & Day (J Hepatol), review of S-adenosylmethionine (SAMe) therapy in liver disease 5
2013Croze & Soulage (Biochimie), review of myo-inositol's role and therapeutic interest in metabolic diseases 17
2013Mato, Martínez-Chantar, Lu (Ann Hepatol), S-adenosylmethionine metabolism and liver disease 4
2013Mehedint & Zeisel (Curr Opin Clin Nutr Metab Care), choline's role in maintaining liver function and epigenetic mechanisms 12
2013Bertolo & McBreairty (Curr Opin Clin Nutr Metab Care), nutritional burden of methylation reactions integrates the methionine-choline-folate-B12 axis 3
2013Stabler (NEJM), clinical practice review of vitamin B12 deficiency 19
2016Wallace & Fulgoni (J Am Coll Nutr), total choline intake assessment from NHANES showing the majority of US adults do not meet the AI 11
2016Sherriff et al 10. (Adv Nutr), review of choline's potential role in NAFLD
2016Pooyandjoo et al 25. (Obes Rev), meta-analysis of oral L-carnitine for weight loss in adults across 9 RCTs
2016Longo, Frigeni, Pasquali (Biochim Biophys Acta), review of carnitine transport and fatty acid oxidation 24
2017Unfer et al 13. (Endocrine Connections), meta-analysis of myo-inositol RCTs in PCOS, the principal evidence base for inositol clinical use
2017Ducker & Rabinowitz (Cell Metabolism), One-Carbon Metabolism in Health and Disease, integrating methionine-folate-B12-choline biology 2
2017Green et al 20. (Nat Rev Dis Primers), comprehensive review of vitamin B12 deficiency
2018Showell et al 14. (Cochrane Database Syst Rev), Cochrane systematic review of inositol for subfertile women with PCOS
2018Smith et al 23. (J Alzheimers Dis), international consensus statement on homocysteine and dementia, anchoring the methionine-B12-folate axis to neurologic outcomes
2021Markun et al 22. (Nutrients), meta-analysis of vitamin B12 supplementation effects on cognition, depressive symptoms, and fatigue
2017-2024FDA issues warning letters to multiple compounding pharmacies and clinics for unsubstantiated weight-loss marketing of lipotropic injection preparations 27
2026McCall et al 26. (Expert Opin Drug Saf), FAERS pharmacovigilance analysis of compounded injectable preparations identifies a distinct adverse-event profile, dosing errors, and sterility-related events not predicted by individual-component evidence
Natural role
Biological Role of Lipotropic Injection (MIC, MICC)
The biological role of the 'lipotropic factors' is historical and descriptive rather than mechanistic in the modern pharmacological sense. The 1930s, 1950s nutritional-deficiency literature established that rats fed a methionine- and choline-deficient diet developed massive hepatic steatosis that could be reversed by re-feeding methionine, choline, or, with smaller effect, inositol, and this is the origin of the term 'lipotropic factor' (literally, fat-mobilizing or fat-tropic) 6. The MCD (methionine-choline-deficient) diet remains a widely used preclinical model of NASH-like liver injury 9.
Translating the lipotropic concept to contemporary human metabolic disease, the relevant biology is the methionine-choline-folate-B12 one-carbon network and its role in maintaining hepatic phosphatidylcholine synthesis, VLDL triglyceride export, glutathione status, and methylation capacity 2. Choline-deficient parenteral nutrition causes reversible hepatic steatosis in adults 7, and population-level choline intake below the AI is common in the United States 11 and is associated with NAFLD 10. This is the strongest mechanistic argument for any role of these nutrients in liver-fat-related metabolic phenotypes. It does not establish a fat-loss claim for systemic adiposity or body weight, and it does not establish that intramuscular injection of milligram doses produces measurable benefit beyond dietary repletion in non-deficient individuals 1.
Clinical contexts studied
Clinical Contexts for Lipotropic Injection (MIC, MICC)
Adjunctive support during medically supervised weight management emerging
Emerging evidence at the combination level. No pivotal RCTs of MIC or MIC+B12 injection demonstrate added weight loss over comprehensive lifestyle and/or pharmacologic therapy. Mechanistic rationale rests on individual-nutrient biology, not on combination-product trials.
There are no FDA-registered phase III trials of lipotropic injection as a weight-loss intervention 27. The combination is dispensed only as an adjunct, on patient-specific prescription, alongside dietary, behavioral, and (where appropriate) FDA-approved pharmacologic weight-management therapy. Individual-component evidence, choline's essential-nutrient status and reversal of hepatic steatosis in deficiency 679, methionine's role in methylation and glutathione synthesis 12, inositol's PCOS RCT base 1314, and modest oral L-carnitine effect sizes 25, supports a mechanistic but unproven combination rationale.
Vitamin B12 deficiency anemia or neuropathy (B12 component alone) well studied
Vitamin B12 alone has well-established evidence for repletion of B12 deficiency states. This is not a labeled indication for the lipotropic combination product.
Intramuscular cyanocobalamin and other B12 forms are well-established for B12 deficiency states (pernicious anemia, post-bariatric malabsorption, dietary deficiency, metformin- or PPI-related deficiency) 192021. Where a patient receiving a lipotropic injection has documented B12 deficiency, the B12 component is the evidence-supported element. The MIC components do not have analogous deficiency-replacement indications, and the combination product itself is not FDA-approved 22.
Fatigue or 'low energy' in adults with documented B12 deficiency emerging
Limited evidence; B12 supplementation effect on fatigue is meta-analyzed with substantial heterogeneity.
Markun et al. (Nutrients 2021) 22 meta-analyzed RCTs of vitamin B12 supplementation on cognitive function, depressive symptoms, and fatigue and reported modest improvement on fatigue scores in pooled analysis, with substantial heterogeneity. The 'energy' marketing claim commonly associated with B12-containing lipotropic injections is supported in patients with documented deficiency but is not supported by current evidence in non-deficient adults 1921.
Polycystic ovary syndrome (inositol component, oral; not lipotropic-injection-specific) well studied
Strong oral inositol RCT base in PCOS, distinct from the injection product. Cited here to anchor the inositol biology, not as an injection indication.
Oral myo-inositol (typically 2, 4 g/day) has been studied in adults with PCOS across multiple RCTs and is meta-analyzed by Unfer et al 151617. (2017) 13 and Showell et al. (Cochrane 2018) 14. Endpoints include ovulatory rate, hyperandrogenism, and insulin sensitivity. The overview of systematic reviews of non-pharmacological PCOS interventions by Pundir et al. (2019) 18 further contextualizes inositol within the broader PCOS evidence landscape. This evidence base is for oral inositol monotherapy and does not transfer to lipotropic injection blends, where inositol is one of several injectable components at compounder-specific concentrations.
Mechanistic and observational evidence links choline status with NAFLD prevalence; controlled human depletion data are clinical-grade. Not an FDA-approved indication for any injectable product.
Adults receiving choline-free parenteral nutrition develop reversible hepatic steatosis and elevated transaminases 7. Observational data in free-living adults link low choline intake to NAFLD prevalence 109. The majority of US adults do not meet the choline AI 11. SAMe therapy in liver disease has been reviewed but is not an FDA-approved injectable indication 54. This evidence supports the mechanistic plausibility of methionine/choline contribution to hepatic phenotype but does not establish a clinical outcome benefit for compounded lipotropic injection specifically 6.
Off-label use
Off-Label Uses of Lipotropic Injection (MIC, MICC)
Compounded use in aesthetic-medicine practice without published RCT support. Marketed weight-loss or fat-spot-reduction claims have been the subject of FDA warning letters.
Lipotropic injection is commonly marketed in aesthetic and concierge weight-loss settings as a 'fat burner' or body-contouring adjunct. The published evidence for this use is limited to anecdotal practice descriptions and small case series; no controlled trial of MIC or MIC+B12 injection has demonstrated localized or systemic fat-loss benefit beyond placebo or beyond comprehensive lifestyle intervention. FDA has issued warning letters to compounding pharmacies and clinics making unsubstantiated weight-loss claims for these preparations 272826.
General wellness, 'energy,' or 'detoxification' marketing emerging
Not supported by controlled evidence. Marketing of compounded injectables for non-disease wellness claims raises 503A and FDA-cosmetic-marketing concerns.
Lipotropic injection has been marketed for generalized 'energy,' 'detoxification,' or 'metabolic boost' purposes in clinic and DTC contexts. The published evidence does not support these claims in non-deficient adults. RonanRx does not dispense lipotropic injection for generalized wellness claims and treats marketing of compounded sterile injectables for non-disease indications as outside the scope of 503Apatient-specific prescription practice 272922.
Compounded lipotropic injection is dispensed only on patient-specific prescription under 503A, prepared in a state-licensed compounding pharmacy under USP <797> sterile-compounding standards 2930. There is no FDA-approved branded lipotropic injection product, so the entire category is by definition a compounded preparation rather than an essentially-a-copy compounding question; FDA's guidance on essentially-a-copy compounded drugs 28 therefore does not directly apply at the combination-product level, though it does apply to individual components such as cyanocobalamin injection, which is commercially available as an FDA-approved injection.
Three distinct regulatory considerations apply. First, the marketing of lipotropic injection for weight loss has been the subject of FDA warning letters when claims exceed what the underlying evidence supports 27. Second, compounded sterile injectable preparations carry distinct safety considerations independent of individual-component biology, sterility, endotoxin, concentration accuracy, container-closure integrity, and beyond-use dating, and the FAERS pharmacovigilance signal for compounded injectables 26 is not predicted by the individual-nutrient evidence base. Third, lipotropic injection is not a substitute for FDA-approved weight-management therapy; patients seeking obesity treatment are best served by evidence-based interventions (lifestyle, semaglutide, tirzepatide, bariatric surgery as appropriate) with lipotropic injection considered only as an adjunct when a documented clinical rationale exists.
RonanRx compounds lipotropic injection on patient-specific prescription, with the prescriber documenting: (1) the clinical rationale for the specific blend chosen (which components, at which concentrations); (2) whether any individual-nutrient deficiency (most commonly B12) is documented and is the primary repletion target; (3) the planned duration and follow-up monitoring; and (4) confirmation that lipotropic injection is being used as adjunct rather than as primary weight-management therapy. RonanRx does not dispense lipotropic injection as a direct-to-consumer product or on aesthetic marketing claims.
Formulations and routes
Lipotropic Injection (MIC, MICC) Formulations and Routes
Form
Concentration
Description
MIC injection (methionine + inositol + choline)
Compounder-specific; commonly 25 mg/mL methionine + 50 mg/mL inositol + 50 mg/mL choline chloride in a 30 mL multi-dose or single-dose vial
Sterile injectable solution prepared under USP <797> on patient-specific prescription. Concentrations vary by compounder; preservative system (typically benzyl alcohol) and pH are documented per batch.30
MIC+B12 injection (MIC + cyanocobalamin or methylcobalamin)
MIC components as above + 1,000 mcg/mL cyanocobalamin or methylcobalamin
MIC blend with vitamin B12 added. The B12 component is the most evidence-supported single ingredient for parenteral administration in adults with documented B12 deficiency [stabler2013, green2017].192030
MIC + B12 as above + L-carnitine (typically 100, 500 mg/mL) + thiamine (B1), riboflavin (B2), dexpanthenol (B5), pyridoxine (B6) at compounder-specific concentrations
Extended formulation incorporating L-carnitine and additional B-complex vitamins. Concentrations and exact constituents are compounder-specific; no consensus formula exists.242530
Routes used in published literature: intramuscular, subcutaneous.
Dosing
Lipotropic Injection (MIC, MICC) Dosing
Route
Population
Range
Duration
Study type
Intramuscular
Adults receiving lipotropic injection as an adjunct to medically supervised weight management
Typically 1 mL injection volume once or twice weekly at compounder-specific component concentrations (e.g., 25 mg methionine + 50 mg inositol + 50 mg choline + 1,000 mcg B12 per 1 mL). No consensus dose-response relationship for the combination has been established in controlled trials.
Indefinite while clinically indicated and as adjunct to active weight-management therapy; no minimum or maximum duration is established by RCT evidence
Compounding-practice convention; no FDA-approved labeled regimen2730
Subcutaneous
Adults, alternative route to intramuscular when IM administration is not preferred
Same 1 mL injection volume at compounder-specific concentrations; subcutaneous administration may produce more local tissue reaction than intramuscular for some component combinations
Indefinite while clinically indicated
Compounding-practice convention; no FDA-approved labeled regimen30
There is no consensus published dose for lipotropic injection 27. Compounders set component concentrations according to historical practice, prescriber preference, and the patient's specific clinical scenario. A typical 1 mL MIC+B12 injection delivers roughly 25 mg methionine, 50 mg inositol, 50 mg choline, and 1,000 mcg B12, doses that are pharmacologically modest relative to oral or parenteral nutrient requirements at the individual-component level. Twice-weekly administration is common; monthly delivery alone is unlikely to provide meaningful nutrient repletion absent a documented deficiency.
Prescribers should document the specific blend ordered, the rationale for each major component, and the planned monitoring strategy. Where the primary clinical objective is B12 repletion, separate FDA-approved cyanocobalamin injection (1,000 mcg IM weekly with taper) is the evidence-based alternative and avoids combination-product variability 1921. Lipotropic injection is not titrated against a dose-response curve; clinical response is assessed against the broader weight-management or repletion plan, not against the injection itself 27.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
Lipotropic Injection (MIC, MICC) Safety
Safety overview
Aggregate human safety experience with lipotropic injection blends derives from clinic case reports and compounding-pharmacy adverse-event reporting rather than from controlled trials. Reported adverse events are dominated by injection-site reactions (pain, erythema, bruising, induration), transient warmth or flushing (often attributable to the methionine or B-vitamin components), nausea, and dysgeusia (a 'metallic' or sulfur taste linked to the methionine and choline components). Mild headache or transient lightheadedness has been reported.
Serious adverse events have included injection-site abscess and cellulitis when sterile technique fails, anaphylaxis to one or more components (most commonly cyanocobalamin or excipients such as benzyl alcohol), and reports of cardiovascular symptoms after rapid intravenous administration of choline at higher doses than typical compounded injection volumes deliver 8. The FAERS pharmacovigilance literature for compounded sterile injectables 26 documents a distinct AE profile, concentration errors, contamination events, and unexpected adverse reactions, that is not predicted by individual-component evidence and that applies to any compounded sterile injectable product.
There are no published cardiovascular outcomes trials, hepatic safety trials, or renal safety trials for the MIC or MIC+B12 combination as an injection. Methionine loading at supraphysiologic doses raises plasma homocysteine acutely, with potential vascular-injury implications in patients with hyperhomocysteinemia; the Smith et al. consensus statement on homocysteine and dementia 23 anchors the long-term relevance of homocysteine. Typical compounded injection doses are too low to be expected to materially shift fasting plasma homocysteine. The mechanistic concern is more pronounced for the choline component in the context of TMAO production by the gut microbiome, long-term high choline exposure has been associated in observational literature with cardiovascular risk markers, but the modest doses delivered in typical compounded injection volumes are not expected to drive clinically meaningful TMAO elevations.
Lipotropic injection is not a substitute for FDA-approved weight-management therapy. Where a patient's clinical objective is meaningful and sustained weight loss, the evidence-based pathway is lifestyle intervention plus FDA-approved pharmacologic therapy (semaglutide, tirzepatide, or others as appropriate) or bariatric surgery, not compounded lipotropic injection 27.
Contraindications
Lipotropic injection is contraindicated in patients with known hypersensitivity to any component or excipient (most commonly cyanocobalamin/cobalt sensitivity or benzyl alcohol hypersensitivity in preservative-containing formulations). Pregnancy and lactation are typical exclusions in the absence of a documented deficiency that warrants component-specific repletion (e.g., B12 deficiency, where FDA-approved cyanocobalamin injection is the preferred pathway) 1920.
Patients with homocystinuria or other inborn errors of methionine metabolism should not receive methionine-containing preparations without consultation with a metabolic specialist. Patients with severe hepatic impairment or active hepatic encephalopathy should not receive methionine-containing parenteral preparations; ammonia and methionine handling are impaired in advanced liver disease. The benzyl alcohol preservative used in many multi-dose compounded preparations is contraindicated in neonates and should be avoided in pregnancy if feasible.
Lipotropic injection should not be used as a substitute for FDA-approved weight-management therapy. Patients with obesity meeting criteria for FDA-approved pharmacotherapy or bariatric surgery should be evaluated for those evidence-based options first; lipotropic injection is at most an adjunct, not a substitute 27.
Drug interactions
Documented drug-interaction data are limited because there is no FDA-registered clinical pharmacology program for the combination. Component-level interactions to consider include: B12 absorption is reduced by long-term metformin and proton-pump inhibitor use 1920, IM B12 (whether alone or as part of a compounded blend) bypasses these absorption issues. Methionine loading interacts with the methionine-homocysteine axis and may augment effects of folate or B6 deficiency.
Choline supplementation has been studied in the context of cholinergic drug effects but at doses far above those delivered in a typical compounded lipotropic injection volume. There are no published controlled drug-interaction studies for MIC or MIC+B12 injection specifically. Co-administration with FDA-approved weight-loss pharmacotherapy (semaglutide, tirzepatide) has not been formally studied; pharmacokinetic interactions are not expected mechanistically, but tolerability of co-administration is not characterized in controlled trials.
Adverse events
Across the compounding-practice literature and clinic reports, the most commonly reported adverse events with lipotropic injection are injection-site reactions (pain, erythema, induration, bruising), transient flushing or warmth, dysgeusia (sulfurous or 'metallic' taste during or shortly after injection, attributable to methionine and choline), mild nausea, and headache 19. Most events are mild, self-limited, and concentrated in the first several injections.
Serious events documented in case reports and pharmacovigilance datasets include: injection-site abscess and cellulitis with breach of sterile technique; anaphylactic and anaphylactoid reactions to cyanocobalamin or to preservatives such as benzyl alcohol; vasovagal syncope at the time of injection; and rare reports of more diffuse hypersensitivity reactions 19. The McCall et al. (2026) FAERS analysis of compounded injectables 26 documents the broader pattern of compounded-sterile-injectable adverse events, including concentration errors, contamination events, and unexpected reactions, that is not predicted by individual-component evidence. The frequency and severity of these events depend on compounding-pharmacy quality systems rather than on the active ingredients.
No long-term cardiovascular, hepatic, renal, or oncologic safety follow-up exists for the MIC or MIC+B12 combination as an injection. Patients should be counseled honestly that the safety database is limited to short-term clinic experience and to the individual-nutrient evidence, not to controlled trials of the combination product 1920.
Baseline assessment should include a focused history (B12 deficiency risk factors including diet, GI disease, metformin/PPI use, age; pregnancy status; allergy history including cobalt and benzyl alcohol; history of homocystinuria or other inborn metabolic errors), a baseline CBC and serum B12 (and homocysteine and/or methylmalonic acid where B12 deficiency is suspected) 192120. Where lipotropic injection is being considered as an adjunct to weight-management therapy, baseline weight, waist circumference, and metabolic labs (HbA1c, lipid panel, ALT/AST) anchor the broader plan against which clinical response is judged.
On therapy: assessment at each injection for injection-site adverse effects and tolerability; periodic CBC and B12 in patients with documented baseline deficiency to confirm hematologic and biochemical correction; weight and waist-circumference tracking against the comprehensive weight-management plan, not against the injection alone. There is no specific lab monitoring schedule supported by RCT evidence for the combination product; monitoring is anchored to the individual clinical scenario and to the patient's broader metabolic care.
Special populations
Lipotropic Injection (MIC, MICC) in Special Populations
Pregnancy
Lipotropic injection is not recommended during pregnancy in the absence of a documented component-specific clinical need. Pregnancy increases choline requirements 6 and B12 requirements, but the appropriate intervention for documented deficiency is FDA-approved component-specific therapy (e.g., prenatal vitamins with choline supplementation; cyanocobalamin injection for documented B12 deficiency), not a multi-component compounded blend 19. Benzyl alcohol preservative used in many compounded multi-dose preparations should be avoided in pregnancy where feasible.
Lactation
There are no controlled data on the use of compounded lipotropic injection in lactating patients. Individual components (B12, choline, methionine, inositol) appear in human milk, and choline requirements increase during lactation 6. The appropriate pathway for documented deficiency is component-specific FDA-approved therapy rather than a compounded multi-nutrient blend.
Pediatric
Lipotropic injection has not been studied in pediatric populations and is not recommended in children or adolescents. Component-specific therapy (e.g., FDA-approved cyanocobalamin for pediatric B12 deficiency) is preferred when a deficiency is documented 19.
Geriatric
Older adults are at higher risk for B12 deficiency due to atrophic gastritis, reduced intrinsic factor, and concomitant medication use (metformin, PPIs) 192021. Where lipotropic injection is being considered in an older adult, the B12 component is typically the most evidence-relevant element. FDA-approved cyanocobalamin injection is the preferred pathway for B12 repletion in geriatric patients; lipotropic injection should be reserved for patients with a documented patient-specific reason for the combination preparation.
Renal impairment
No formal dose-adjustment data exist for the combination product. Cyanocobalamin clearance is unchanged in renal impairment; methionine and choline metabolism may be altered in advanced kidney disease. There are no published pharmacokinetic data for compounded MIC or MIC+B12 injections in chronic kidney disease populations 19.
Hepatic impairment
Methionine handling is impaired in advanced hepatic disease, and methionine-containing preparations should be avoided in active hepatic encephalopathy or severe hepatic impairment. Choline status is relevant to hepatic phenotype 910 but parenteral choline repletion is not established as a treatment for clinical NAFLD or MASH outside the parenteral-nutrition setting 7. SAMe therapy in liver disease has been reviewed 54 but is not FDA-approved as an injectable indication.
Evidence quality
Lipotropic Injection (MIC, MICC) Evidence Quality
Evidence supporting compounded lipotropic injection breaks down into two tiers 5679. At the individual-component level the evidence is substantial for several constituents: choline is an FDA-recognized essential nutrient with controlled human depletion-repletion data establishing its requirement and a clear link to hepatic steatosis in deficiency; methionine's role in the one-carbon network and glutathione synthesis is foundational nutritional biochemistry; vitamin B12 deficiency and its treatment with parenteral cobalamin are clinical-grade evidence; inositol has a meaningful RCT base in PCOS; L-carnitine has modest oral weight-loss meta-analytic effect sizes 2524138. The integrated methionine-choline-folate-B12 axis is a well-characterized methylation and lipid-export pathway 231210.
At the combination-product level the evidence is Tier 3 (emerging) and rests on clinic practice tradition, compounding-pharmacy case series, and aesthetic-medicine descriptions rather than on pivotal trials 191411. There are no FDA-registered phase I/II/III trials of MIC or MIC+B12 injection for weight management, hepatic phenotype, or 'energy.' FDA has issued warning letters to compounding pharmacies and clinics for unsubstantiated weight-loss marketing claims about lipotropic injection 271522. Compounded sterile injectable preparations carry distinct pharmacovigilance considerations 26 that are not predicted by the individual-component evidence 2021. RonanRx frames lipotropic injection honestly to prescribers and patients as a 503A patient-specific adjunct with mechanistic but not outcome-trial support, not as an FDA-approved or evidence-equivalent alternative to weight-management therapy 141617.
Major studies
Major Lipotropic Injection (MIC, MICC) Clinical Studies
Placebo-controlled trial of choline supplementation in adults receiving long-term parenteral nutrition
—
Multi-week intervention with hepatic-imaging and biochemistry endpoints
Choline deficiency caused reversible hepatic steatosis and elevated transaminases in adults on choline-free parenteral nutrition; choline repletion normalized hepatic findings, established the human choline requirement 7
Established the public-health framing of choline as an essential nutrient required for phosphatidylcholine synthesis, methylation, and neurodevelopment; underpins the Institute of Medicine Adequate Intake recommendations 6
Majority of US adults do not meet the Adequate Intake recommendation for choline; population-level rationale for choline-relevant repletion strategies 11
Authoritative review of methionine and cysteine nutritional biochemistry
—
—
Anchored methionine's role as the principal methyl donor (via SAMe) and as a precursor for glutathione synthesis through the transsulfuration pathway 1
Synthesized the one-carbon network and its relevance to methylation, redox, and lipid handling; the integrative biology that motivates lipotropic-injection rationale 2
Reviewed RCT evidence for S-adenosylmethionine in liver disease, noting limited but supportive data in intrahepatic cholestasis of pregnancy and alcoholic liver disease 5
Systematic review and meta-analysis of randomized controlled trials of myo-inositol in adults with PCOS
—
—
Pooled analysis demonstrated improvements in ovulatory rate, hyperandrogenism markers, and insulin sensitivity with oral myo-inositol vs control, the principal evidence base for clinical inositol use 13
Evaluated inositol supplementation for subfertile women with PCOS; reported low-to-moderate quality evidence for benefits on ovulation and pregnancy outcomes 14
Authoritative clinical synthesis of B12 deficiency diagnosis and treatment; intramuscular cyanocobalamin remains the reference parenteral repletion approach in malabsorption states 19
Multi-author consensus review of B12 deficiency biology, epidemiology, diagnosis, and treatment, anchoring the evidence base for parenteral cobalamin 20
Systematic review, meta-analysis, and meta-regression of RCTs of B12 supplementation
—
—
Pooled analysis suggested modest improvement in fatigue scores with B12 supplementation, with substantial heterogeneity; cognitive and depressive-symptom benefits less consistent 22
Systematic review and meta-analysis of 9 RCTs of oral L-carnitine for weight loss in adults
—
—
Pooled mean weight reduction of approximately 1.3 kg with L-carnitine vs control, modest effect size; relevant for MIC+ formulations containing carnitine but at doses below those in the pooled trials 25
International consensus statement of nutritional and neurology experts
—
—
Elevated homocysteine is a modifiable risk factor for cognitive decline and dementia; B12 + folate + B6 repletion reduces homocysteine and may slow cognitive decline in specific subgroups 23
Pharmacovigilance analysis of FDA Adverse Event Reporting System data for compounded injectable preparations
—
—
Documented a distinct adverse-event profile for compounded sterile injectables, dosing errors, contamination, and unexpected events, not predicted by individual-component evidence; framework applies to compounded lipotropic injection 26
Mechanism detail
Detailed Mechanism of Lipotropic Injection (MIC, MICC)
Methionine sits at the head of the methionine-homocysteine cycle. Through ATP-dependent activation by methionine adenosyltransferase, methionine generates S-adenosylmethionine (SAMe), the universal donor for cellular methylation reactions, including phosphatidylcholine biosynthesis via the PEMT pathway, DNA and histone methylation, and neurotransmitter synthesis 124. After methyl donation SAMe becomes S-adenosylhomocysteine and is hydrolyzed to homocysteine, which can be either remethylated to methionine (using a methyl group from 5-methyl-tetrahydrofolate, with vitamin B12 as the methionine-synthase cofactor) or transsulfurated through cystathionine β-synthase (a B6-dependent enzyme) to cysteine, the rate-limiting precursor of glutathione 123. The methionine-choline-folate-B12-B6 network therefore represents a single integrated nutrient axis; deficiency in any single node propagates downstream and shows the same biochemical fingerprint (elevated homocysteine, reduced methylation potential, impaired glutathione synthesis).
Choline is an essential nutrient with an Adequate Intake established by the Institute of Medicine in 1998 (425, 550 mg/day for adults; higher in pregnancy and lactation) 4. Choline supports phosphatidylcholine synthesis through both the CDP-choline (Kennedy) pathway and, through the PEMT pathway, by methylation of phosphatidylethanolamine using SAMe, a pathway that links choline biology directly to methionine status 6129. Phosphatidylcholine is required for VLDL particle assembly and triglyceride export from hepatocytes; the controlled human depletion-repletion studies of Buchman and colleagues established that adults receiving choline-free parenteral nutrition develop hepatic steatosis and elevated transaminases that reverse on choline repletion 78. Population-level data show that the majority of US adults do not meet the AI for choline 11, and observational data link low choline intake with NAFLD prevalence 109.
Inositol exists as nine stereoisomers; myo-inositol is the dominant physiologic form, with D-chiro-inositol a smaller pool that contributes to insulin-signaling lipid mediators 4. Inositol participates in phosphoinositide second-messenger systems, including phosphatidylinositol-(4,5)-bisphosphate signaling downstream of insulin, FSH, and TSH receptors 17. The strongest randomized-trial evidence is in polycystic ovary syndrome, where myo-inositol supplementation (typically 2, 4 g/day orally) has produced improvements in ovulatory rate, hyperandrogenism, and insulin sensitivity in meta-analysis 131514. The combined myo-inositol + D-chiro-inositol formulation at the physiologic 40:1 plasma ratio has been studied for additional metabolic effect 16. Inositol's relevance to lipotropic-injection rationale is mechanistic (insulin sensitization, ovarian/metabolic signaling) rather than directly established for parenteral fat-loss endpoints.
Vitamin B12 in compounded preparations is supplied as cyanocobalamin (the most stable form, requiring intracellular conversion to active coenzymes) or methylcobalamin (the methylated coenzyme form active in methionine synthase) 4. B12 deficiency is common in populations with malabsorption, pernicious anemia, vegan diets, chronic metformin or PPI use, and advanced age; presentations range from megaloblastic anemia and macrocytosis to subacute combined degeneration of the spinal cord, peripheral neuropathy, cognitive impairment, and fatigue 192021. Cobalamin is among the few water-soluble vitamins where parenteral administration has a clear evidence-based role: in pernicious anemia and other malabsorption states, intramuscular cyanocobalamin reliably corrects hematologic and neurologic findings where oral repletion may be insufficient. The Markun et al. meta-analysis 22 evaluated B12 supplementation effects on cognition, depressive symptoms, and fatigue and found improvement in fatigue scores in pooled analysis, though heterogeneity is substantial. The 'energy' claim for B12 in lipotropic injection is therefore physiologically anchored where deficiency is present, but does not translate to non-deficient populations.
L-carnitine, when present in MIC+ formulations, transports activated long-chain fatty acids across the outer mitochondrial membrane (as acyl-carnitine) via the carnitine palmitoyltransferase shuttle, supporting hepatic and skeletal-muscle fatty-acid oxidation 244. Meta-analysis of oral L-carnitine for weight loss in adults 25 reported a pooled mean weight reduction of approximately 1.3 kg vs control across 9 randomized trials, a modest effect size that does not translate directly to the much lower doses typical in compounded MIC+ injection volumes.
There are no published pharmacokinetic data for compounded MIC or MIC+B12 injection blends as combination products. Individual-component pharmacokinetics are characterized: choline plasma kinetics after IV infusion have been described in adult subjects 8; cyanocobalamin and methylcobalamin pharmacokinetics after IM administration are well established with rapid absorption and prolonged tissue retention via transcobalamin and liver storage 1920; myo-inositol and methionine oral pharmacokinetics are characterized but parenteral data are sparse.
Compounded preparations may differ between compounders in concentration, preservative system, and pH; PK characteristics published for individual components in research settings should not be assumed to translate directly to a compounded multi-component injection. There are no bioequivalence data for any compounded lipotropic injection product.
Pharmacodynamics
Pharmacodynamic endpoints for lipotropic injection are not standardized. Where the B12 component is the clinical target, hematologic correction (reticulocytosis, normalization of MCV) and biochemical correction (homocysteine, methylmalonic acid) follow standard patterns for parenteral cyanocobalamin 192021. Where weight management is the clinical target, the relevant endpoints (body weight, body composition, waist circumference, metabolic markers) are anchored to the broader weight-management plan, not to the injection alone; no controlled trial has demonstrated a measurable PD signal of the MIC or MIC+B12 combination on these endpoints independent of concurrent lifestyle or pharmacologic therapy.
There is no reference FDA-approved branded lipotropic injection against which a compounded preparation can be benchmarked. The closest single-component FDA-approved comparator is cyanocobalamin injection, which carries an FDA-approved label in B12 deficiency and is available as a manufactured product. For the methionine, inositol, choline, and L-carnitine components, no FDA-approved injectable products exist for the weight-management or general-wellness use cases that motivate lipotropic-injection prescribing.
Compounded MIC vs MIC+B12 vs MIC+ (with carnitine and additional B-vitamins) formulations differ at the prescribing-decision level. MIC alone delivers the three classical lipotropic factors; MIC+B12 adds the most evidence-supported single-component repletion option for patients with documented or likely B12 deficiency 1920; MIC+ adds L-carnitine and supplementary B-vitamins with additional mechanistic but no proven combination-product effect. RonanRx recommends prescribers choose the simplest formulation that addresses the documented clinical objective.
Storage
Lipotropic Injection (MIC, MICC) Storage and Handling
Compounded lipotropic injection is stored according to the compounding pharmacy's stability data and beyond-use date assignment under USP <797> 30. Multi-dose preservative-containing preparations are typically stored refrigerated (2, 8°C) and may be stable for several weeks; preservative-free single-dose preparations have shorter beyond-use dates. Patients should be educated on refrigeration on receipt and on inspecting for particulate matter, discoloration, or precipitation before each use.
Compounded lipotropic injection is prepared under 503A on patient-specific prescriptions in state-licensed compounding pharmacies. RonanRx prepares the sterile injectable preparation per USP General Chapter <797>, with documented active-ingredient sourcing for each component, gravimetric and analytical verification, sterility and endotoxin testing per the pharmacy's quality-management system, and full lot traceability 30. For any nonsterile preparative steps the corresponding USP General Chapter <795> applies; however, the finished injectable product is governed by <797> in full 31.
Because there is no FDA-approved branded lipotropic injection product, the 'essentially-a-copy' restriction does not apply at the combination-product level 28, but it does apply to the individual cyanocobalamin component, which is commercially available as an FDA-approved injection, compounding cyanocobalamin alone as a copy of the FDA-approved product is restricted to documented patient-specific clinical need. RonanRx documents the patient-specific clinical rationale for each lipotropic-injection prescription and does not dispense the product as a routine, marketing-driven, or DTC offering 2927.
Pharmacist review
Each prescription for compounded lipotropic injection undergoes pharmacist review prior to dispensing 28. The review confirms: a documented patient-specific clinical rationale (which components, at which concentrations, for which clinical objective, repletion of documented B12 deficiency, adjunct to active weight-management plan, or other documented purpose); absence of contraindications (hypersensitivity to components or preservatives; pregnancy without specific documented need; severe hepatic impairment or homocystinuria for methionine-containing preparations); concomitant medication review (metformin and PPIs as B12 absorption modifiers; co-administration with weight-management pharmacotherapy); and confirmation that the patient is not receiving lipotropic injection as a substitute for FDA-approved weight-management therapy.
RonanRx does not fill prescriptions that read as DTC marketing, aesthetic 'fat-burner' branding, or generalized wellness use without a documented patient-specific clinical rationale, consistent with FDA guidance and warning-letter precedent on compounded lipotropic injection marketing 272928. Pharmacovigilance signals specific to compounded sterile injectables 26 reinforce the review threshold.
Quality and traceability
Active pharmaceutical ingredients for each component (methionine, inositol, choline chloride or bitartrate, cyanocobalamin or methylcobalamin, and any additional B-vitamins or L-carnitine in MIC+ formulations) are sourced from FDA-registered facilities with documented certificates of analysis. Each batch is recorded with lot numbers traceable to each API source, compounding date, beyond-use date, sterility test result, endotoxin test result, and dispensing pharmacist of record. Finished-product lot records are retained per state board of pharmacy retention requirements.
Cold chain
Compounded lipotropic injection is typically refrigerated. Refrigerated transport is used between the compounding pharmacy and the patient with temperature monitoring through the shipment. Patients are advised to refrigerate the product on arrival, to inspect for temperature excursions, particulate matter, discoloration, or precipitation, and to contact the pharmacy if cold-chain integrity is in question or visual inspection raises concern.
FAQ
Frequently Asked Questions About Lipotropic Injection (MIC, MICC)
Is lipotropic injection FDA-approved?
No. There is no FDA-approved branded lipotropic injection product. The combination is prepared under 503A on patient-specific prescription. Individual components have their own regulatory status, for example, cyanocobalamin injection carries an FDA-approved label in B12 deficiency, but the multi-component lipotropic blend does not 2927.
Does lipotropic injection cause weight loss?
There are no pivotal randomized controlled trials demonstrating that lipotropic injection causes weight loss on its own 25. The published evidence for the combination is at the case-series and clinic-experience level. Patients seeking meaningful and durable weight loss are best served by lifestyle intervention plus FDA-approved pharmacotherapy (such as semaglutide or tirzepatide) or bariatric surgery, with lipotropic injection considered at most as an adjunct under physician supervision 27.
What is in a typical MIC or MIC+B12 injection?
A typical MIC injection contains methionine, inositol, and choline 6. MIC+B12 adds vitamin B12 (cyanocobalamin or methylcobalamin) 19. Extended 'MIC+' or 'lipo-Mino' blends may also contain L-carnitine and additional B-vitamins (B1, B2, B5, B6). Exact concentrations vary by compounding pharmacy, there is no standardized formula 117.
Is the 'energy boost' from B12 in lipotropic injection real?
In patients with documented vitamin B12 deficiency, correcting B12 reliably improves fatigue, neurologic symptoms, and anemia 1920. In adults without B12 deficiency, controlled evidence for an 'energy boost' from B12 supplementation is limited; the Markun 2021 meta-analysis reported modest improvement in fatigue scores with B12 supplementation but with substantial heterogeneity 22. Lipotropic injection should not be marketed as an energy boost in non-deficient patients.
Are there side effects?
Most commonly: injection-site pain, redness, bruising, transient flushing, a metallic or sulfurous taste, mild nausea, or headache. Serious events have been reported in case reports, injection-site infection, anaphylaxis to cyanocobalamin or preservatives, and the broader pharmacovigilance pattern for compounded sterile injectables 26. Long-term outcome data do not exist for the combination product 19.
Who should not use lipotropic injection?
Patients with hypersensitivity to any component (especially cobalt/B12 or benzyl alcohol preservative), homocystinuria or other inborn errors of methionine metabolism, severe hepatic impairment or hepatic encephalopathy, and patients in pregnancy or lactation without a documented component-specific clinical need 19. It is also not appropriate as a substitute for FDA-approved weight-loss therapy in patients who would benefit from those evidence-based options 6.
Does RonanRx sell lipotropic injection direct to consumers?
No. Lipotropic injection requires a patient-specific prescription written by a licensed doctor for an identified patient with a documented clinical rationale, plus pharmacist review before dispensing 27. RonanRx is not a direct-to-consumer storefront and does not fill prescriptions that read as marketing-driven 'fat burner' or generalized wellness products 29.
Clinician resource
Download the Lipotropic Injection (MIC, MICC) Clinical Monograph (PDF)
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
[brosnan2006] Brosnan JT, Brosnan ME. The sulfur-containing amino acids: an overview. Journal of Nutrition. 2006. PMID 16702333. (accessed 2026-05-11)
[ducker2017] Ducker GS, Rabinowitz JD. One-Carbon Metabolism in Health and Disease. Cell Metabolism. 2017. PMID 27641100. (accessed 2026-05-11)
[bertolo2013] Bertolo RF, McBreairty LE. The nutritional burden of methylation reactions. Current Opinion in Clinical Nutrition and Metabolic Care. 2013. PMID 23196816. (accessed 2026-05-11)
[mato2013] Mato JM, Martínez-Chantar ML, Lu SC. S-adenosylmethionine metabolism and liver disease. Annals of Hepatology. 2013. PMID 23396728. (accessed 2026-05-11)
[anstee2012] Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. Journal of Hepatology. 2012. PMID 22659519. (accessed 2026-05-11)
[zeisel2009] Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. Nutrition Reviews. 2009. PMID 19906248. (accessed 2026-05-11)
[buchman2001] Buchman AL, Ament ME, Sohel M, Dubin M, Jenden DJ, Roch M, Pownall H, Farley W, Awal M, Ahn C. Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition. 2001. PMID 11531217. (accessed 2026-05-11)
[buchman1994] Buchman AL, Jenden DJ, Moukarzel AA, Roch M, Rice KM, Chang AS, Ament ME. Choline pharmacokinetics during intermittent intravenous choline infusion in human subjects. Clinical Pharmacology and Therapeutics. 1994. PMID 8143393. (accessed 2026-05-11)
[corbin2012] Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Current Opinion in Gastroenterology. 2012. PMID 22134222. (accessed 2026-05-11)
[sherriff2016] Sherriff JL, O'Sullivan TA, Properzi C, Oddo JL, Adams LA. Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes. Advances in Nutrition. 2016. PMID 26773011. (accessed 2026-05-11)
[wallace2016] Wallace TC, Fulgoni VL 3rd. Assessment of Total Choline Intakes in the United States. Journal of the American College of Nutrition. 2016. PMID 26886842. (accessed 2026-05-11)
[mehedint2013] Mehedint MG, Zeisel SH. Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Current Opinion in Clinical Nutrition and Metabolic Care. 2013. PMID 23493015. (accessed 2026-05-11)
[unfer2017] Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections. 2017. PMID 29042448. (accessed 2026-05-11)
[showell2018] Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2018. PMID 30570133. (accessed 2026-05-11)
[carlomagno2012] Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecological Endocrinology. 2012. PMID 22296306. (accessed 2026-05-11)
[nordio2012] Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. European Review for Medical and Pharmacological Sciences. 2012. PMID 22774396. (accessed 2026-05-11)
[croze2013] Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013. PMID 23764390. (accessed 2026-05-11)
[pundir2019] Pundir J, Charles D, Sabatini L, Hiam D, Jitpiriyaroj S, Teede H, Coomarasamy A, Moran L, Thangaratinam S. Overview of systematic reviews of non-pharmacological interventions in women with polycystic ovary syndrome. Human Reproduction Update. 2019. PMID 30608609. (accessed 2026-05-11)
[stabler2013] Stabler SP. Clinical practice. Vitamin B12 deficiency. New England Journal of Medicine. 2013. PMID 23301732. (accessed 2026-05-11)
[green2017] Green R, Allen LH, Bjørke-Monsen AL, Brito A, Guéant JL, Miller JW, Molloy AM, Nexo E, Stabler S, Toh BH, Ueland PM, Yajnik C. Vitamin B(12) deficiency. Nature Reviews Disease Primers. 2017. PMID 28660890. (accessed 2026-05-11)
[hunt2014] Hunt A, Harrington D, Robinson S. Vitamin B12 deficiency. BMJ. 2014. PMID 25189324. (accessed 2026-05-11)
[markun2021] Markun S, Gravestock I, Jäger L, Rosemann T, Pichierri G, Burgstaller JM. Effects of Vitamin B12 Supplementation on Cognitive Function, Depressive Symptoms, and Fatigue: A Systematic Review, Meta-Analysis, and Meta-Regression. Nutrients. 2021. PMID 33809274. (accessed 2026-05-11)
[smith2018] Smith AD, Refsum H, Bottiglieri T, Fenech M, Hooshmand B, McCaddon A, Miller JW, Rosenberg IH, Obeid R. Homocysteine and Dementia: An International Consensus Statement. Journal of Alzheimer's Disease. 2018. PMID 29480200. (accessed 2026-05-11)
[longo2016] Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochimica et Biophysica Acta. 2016. PMID 26828774. (accessed 2026-05-11)
[pooyandjoo2016] Pooyandjoo M, Nouhi M, Shab-Bidar S, Djafarian K, Olyaeemanesh A. The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. Obesity Reviews. 2016. PMID 27335245. (accessed 2026-05-11)
[mccall2026] McCall KL, Piper BJ, Bothwell P, Tan JN, Nichols SD. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opinion on Drug Safety. 2026. PMID 40285721. (accessed 2026-05-11)
[fda_essentially_a_copy] U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry. FDA Guidance for Industry. 2018. https://www.fda.gov/media/98973/download (accessed 2026-05-11)
[usp_797] United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-797 (accessed 2026-05-11)
[usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)
How to access
How to Access Lipotropic Injection (MIC, MICC)
Compounded Lipotropic Injection (MIC, MICC) is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.
For doctors
Offer this medication.
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
If your doctor has already prescribed Lipotropic Injection (MIC, MICC), sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Lipotropic Injection (MIC, MICC).
